Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Treasury Shares (2016 - 2025)

Iovance Biotherapeutics has reported Treasury Shares over the past 9 years, most recently at $9.9 million for Q3 2025.

  • Quarterly results put Treasury Shares at $9.9 million for Q3 2025, changed 0.31% from a year ago — trailing twelve months through Sep 2025 was $9.9 million (changed 0.31% YoY), and the annual figure for FY2024 was $9.5 million, up 176.43%.
  • Treasury Shares for Q3 2025 was $9.9 million at Iovance Biotherapeutics, down from $11.4 million in the prior quarter.
  • Over the last five years, Treasury Shares for IOVA hit a ceiling of $12.2 million in Q1 2025 and a floor of $3.5 million in Q4 2023.
  • Median Treasury Shares over the past 3 years was $9.9 million (2025), compared with a mean of $8.4 million.
  • Biggest five-year swings in Treasury Shares: surged 208.93% in 2024 and later fell 3.6% in 2025.
  • Iovance Biotherapeutics' Treasury Shares stood at $3.5 million in 2023, then surged by 176.43% to $9.5 million in 2024, then rose by 3.53% to $9.9 million in 2025.
  • The last three reported values for Treasury Shares were $9.9 million (Q3 2025), $11.4 million (Q2 2025), and $12.2 million (Q1 2025) per Business Quant data.